PANEL MEMBERS

Nathan Clumeck, Treasurer
Chair, Brussels, Belgium

Anton Pozniak,
London, United Kingdom

François Raffi,
Nantes, France

And the European AIDS Clinical Society
Executive Committee

Antonella d’Arminio Monforte,
Milan, Italy

Manuel Battegay,
Basel, Switzerland

Nathan Clumeck,
Brussels, Belgium

Jose Gatell, President
Barcelona, Spain

Andrzej Horban,
Warsaw, Poland

Christine Katlama,
Paris, France

Jens Lundgren,
Hvidovre, Denmark

Santiago Moreno,
Madrid, Spain

Fiona Mulcahy, Secretary
Dublin, Ireland

Anton Pozniak,
London, United Kingdom

François Raffi,
Nantes, France

Peter Reiss, President Elect
Amsterdam, The Netherlands

Jürgen Rockstroh,
Bonn, Germany

Schlomo Staszewski,
Frankfurt, Germany

Mike Youle,
London, United Kingdom
Initial visit

- Complete medical history
- Physical examination, including height, weight, BMI, blood pressure
- Laboratory evaluation
  - Confirmation of HIV antibody positive
  - Plasma HIV RNA
  - Resistance testing (genotype) with determination of HIV subtype
  - CD4 absolute count + percentage (optional: CD8 and %)
  - Complete blood count, AST, ALT, Alk phosphatase, calcium phosphate, glucose, creatinine, calculated creatinine clearance
  - Antibody tests for toxoplasma, CMV, Hepatitis A, B and C, and syphilis
  - Fasting blood glucose and lipids including fasting total LDL & HDL cholesterol, and triglycerides (see metabolic guidelines)

- Urine dipstick for protein and sugar
- HLA B*5701 determination (if available)
- Sexually Transmitted Infection screen if appropriate
- Women: cervical pap smear
- Assessment of social and psychological condition: provide support and counselling if needed
- Consider HAV and HBV vaccination (depending on serology results) and pneumococcal vaccination

Subsequent visits

(Asymptomatic patients not receiving antiretroviral therapy)

- At least every 6 months
  - Complete blood count, CD4 count and %, plasma HIV RNA
- Every year
  - Physical examination
  - Evaluation of social and psychological support, smoking cessation
Assessment Of HIV Infected Patients at Initial and Subsequent Visits -1/2-

- Repeat serologic testing (syphilis, CMV, toxoplasmosis, hepatitis B, hepatitis C) if previously negative
- AST, ALT
- Women: cervical pap smear
- If cirrhosis (regardless of cause): alphafoetoprotein + ultrasound examination
- Fasting lipids

Treatment initiation
- Physical examination, including height, weight, BMI, blood pressure
- Plasma HIV RNA
- Resistance testing (genotype), if not yet obtained
- CD4 count and % (optional: CD8 count and %)
- Complete blood count, AST, ALT, bilirubin, creatinine, calculated creatinine clearance, calcium, phosphate
- Fasting glucose and lipids
- Urine dipstick for protein and sugar
- Other laboratory parameters may be useful according to selected first-line regimen eg protein creatinine ratio, amylase, lipase

Visits on therapy
- Plasma HIV RNA
- CD4 count and % (optional: CD8 count and %)
- Complete blood count, creatinine, calculated creatinine clearance, AST, ALT bilirubin
- Other laboratory parameters according to selected regimen
- Fasting glucose and lipids
Primary HIV infection (PHI)

Definition of Acute primary HIV infection
- High risk exposure within previous 2-8 weeks,
- and Clinical symptoms,
- and detectable HIV in the plasma (p24 Ag and/or HIV RNA > 10 000 c/ml)
- and negative or indeterminate serologic testing (negative or weakly positive ELISA, and WB ≤ 1 band)

Recommendation: confirm HIV infection by HIV antibody test (WB) performed 3-6 weeks later.

Treatment:
- Favour clinical trial
- Treatment indicated if:
  - AIDS defining events
  - confirmed CD4 <350/mm3 at month 3 or beyond
- Treatment should be considered if
  - Severe illness/prolonged symptoms (especially CNS symptoms)
- Treatment optional, as indication relies only on theoretical considerations. In most situations, wait till month 6 (with CD4 and plasma HIV-RNA monitoring) and follow criteria for initiation of treatment in chronic HIV infection. Some experts recommend treatment as a tool for prevention of HIV transmission.

Duration of treatment: unknown but maybe should be lifelong. Maintain closer follow-up in case of treatment interruption.

Resistance testing:
- Recommended in all situations as soon as acute HIV infection is diagnosed, even if treatment not initiated
- In case it cannot be performed, store blood for further testing.

Transmission:
- Recognize sexually transmitted infections (STIs), including syphilis, gonorrhoea, Chlamydia (urethritis and LGV), HPV, hepatitis B and hepatitis C.
- Counsel newly diagnosed patient on high risk of transmission and preventive measures (condoms) including notifying and testing partners.
# Recommendations for Initiation of Therapy in Naive HIV-Infected Patients

<table>
<thead>
<tr>
<th>Symptomatic</th>
<th>Asymptomatic</th>
<th>Resistance testing</th>
<th>Additional remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC stage B and C: treatment recommended.</td>
<td>CD4 &lt; 200: Treatment recommended, without delay.</td>
<td>Genotypic testing and subtype determination recommended, ideally at the time of HIV diagnosis, otherwise before initiation of first-line regimen</td>
<td>Before starting treatment, CD4 should be repeated and confirmed</td>
</tr>
<tr>
<td>If OI, initiate as soon as possible*</td>
<td>CD4 201-350: treatment recommended.</td>
<td>If genotypic testing is not available, a ritonavir-boosted PI could be preferred in the first-line regimen</td>
<td>Time should be taken to prepare the patient, in order to optimize compliance and adherence</td>
</tr>
<tr>
<td>CD4 350-500: treatment may be offered if VL &gt; 10^5 c/ml and/or CD4 decline &gt;50-100/mm3/year or age &gt;55 or hepatitis C co-infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 &gt; 500: treatment should be deferred, independently of Plasma HIV RNA; closer follow-up of CD4 if VL &gt; 10^5 c/ml.</td>
<td>Whatever CD4 and Plasma HIV RNA, treatment can be offered on an individual basis, especially if patient seeking and ready for ARV therapy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Pay particular attention to drug-drug interactions, drug toxicities, immune reconstitution syndrome and adherence, etc...
## Initial Combination Regimen for Antiretroviral-Naïve patient

<table>
<thead>
<tr>
<th>Select 1 drug in column A and 1 NRTI combination in column B</th>
<th>A</th>
<th>B</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommended</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NNRTI</td>
<td></td>
<td>ABC/3TC&lt;sup&gt;2&lt;/sup&gt;</td>
<td>• ABC/3TC co-formulated</td>
</tr>
<tr>
<td>• EFV&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
<td>TDF/FTC</td>
<td>• TDF/FTC co-formulated</td>
</tr>
<tr>
<td>• NVP&lt;sup&gt;4&lt;/sup&gt; or ritonavir-boosted PI</td>
<td></td>
<td></td>
<td>• fAPV/r: 700/100 mg bid</td>
</tr>
<tr>
<td>• fAPV/r</td>
<td></td>
<td></td>
<td>or 1400/200 mg qd</td>
</tr>
<tr>
<td>• LPV/r</td>
<td></td>
<td></td>
<td>• LPV/r: 400/100 mg bid</td>
</tr>
<tr>
<td>• SQV/r</td>
<td></td>
<td></td>
<td>or 800/200 mg qd</td>
</tr>
<tr>
<td><strong>Alternative</strong></td>
<td></td>
<td>ZDV/3TC</td>
<td>ZDV/3TC co-formulated</td>
</tr>
<tr>
<td>ATV/r&lt;sup&gt;5&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. EFV: not recommended in pregnant women or women with no reliable and consistent contraception; not active on HIV-2 and HIV-1 group O
2. Contra-indicated if HLA B*5701 positive. Even if HLA B*5701 negative, counselling on HSR risk still mandatory
3. ABC + NVP contra-indicated, unless HLA B*5701 negative
4. NVP: Use with extreme caution in women with CD4 >250 and men with CD4 >400/μL; not active on HIV-2 and HIV-1 group O
5. Approved by FDA but not yet approved by EMEA. Some physicians use ATV/r in first line regimen
6. Only if unavailable or intolerant to other recommended NRTIs
### Virologic Failure

**Definition**
Confirmed Plasma HIV RNA > 50 copies/ml 6 months after starting therapy (initiation or modification) in patients that remains on ART

**General measures**
- Evaluate adherence, compliance, tolerability, drug-drug interactions, drug-food interactions, psychosocial issues
- Perform resistance testing on failing therapy (usually reliable with plasma HIV RNA levels >500-1000 copies/ml) and obtain historical resistance testing for archived mutations
- Consider TDM
- Review antiretroviral history
- Identify treatment options, active, potentially active drugs/combinations

#### Management of virologic failure (VF)

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>If Plasma HIV RNA &gt; 50 and &lt;500-1000 copies/ml</td>
<td>- Check for adherence&lt;br&gt;- Check Plasma HIV RNA 1 to 2 months later&lt;br&gt;- Improve boosted PI's PK (if applicable)</td>
</tr>
<tr>
<td>If Plasma HIV RNA confirmed &gt; 500/1000 copies/ml, change regimen as soon as possible: what to change will depend on the resistance testing results:</td>
<td>- No Resistance mutations found: re-check for adherence, perform TDM&lt;br&gt;- Resistance mutations found: switch to a suppressive regimen based on drug history; multidisciplinary experts discussion advised</td>
</tr>
<tr>
<td>Goal of new regimen: Plasma HIV RNA &lt; 400 c/ml after 3 months, Plasma HIV RNA &lt; 50 c/ml after 6 months</td>
<td></td>
</tr>
</tbody>
</table>

#### In case of resistance mutations demonstrated

General recommendations:
- Use 2 or preferably 3 active drugs in the new regimen (including active drugs from previously used classes)
- Any regimen should use at least 1 drug from a class not used previously e.g. fusion, integrase or CCR inhibitor
- Defer change if < 2 active drugs available, based on resistance data, except in patients with low CD4 count (<100/mm3) or with high risk of clinical deterioration for whom the goal is the preservation of immune function through partial reduction of Plasma HIV RNA (> 1 log reduction) by recycling.
- If limited options, consider experimental and new mechanistic drugs, favouring clinical trials (but avoid functional monotherapy)
- Treatment interruption is not recommended

Optimisation of new regimen:
- Avoid NNRTI in NNRTI-experienced patients; Etravirine potentially active in selected NNRTI-resistance profiles
- Consider continuation of 3TC or FTC even if documented resistance mutation (M184V/I)
- Select other potentially active NRTI(s), on treatment history and full resistance (past and present) evaluation
- Select 1 active ritonavir-boosted PI. If at all possible avoid double boosted PIs
- Always check for drug-drug-interactions, and when necessary perform TDM of drugs of new regimen if available

If many options are available, criteria of preferred choice include: simplicity of the regimen, toxicity risks evaluation, drug-drug-interactions, future salvage therapy
Pregnant women should be monitored every month and as close as possible to the predicted delivery date.

<table>
<thead>
<tr>
<th>Criteria for starting ART in pregnant women (see different scenario’s)</th>
<th>Same as for non pregnant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective of treatment in pregnant women</td>
<td>Full Plasma HIV RNA suppression by third trimester and specifically at time of delivery</td>
</tr>
<tr>
<td>Resistance testing</td>
<td>Same as for non pregnant, i.e. before starting ART and in case of virologic failure</td>
</tr>
</tbody>
</table>

**SCENARIO**

1. Women becoming pregnant while already on ART  
2. Women becoming pregnant while treatment naïve and who fulfil the criteria (CD4) for initiation of ART  
3. Women becoming pregnant while treatment naïve and who do not fulfil the criteria (CD4) for initiation of ART  
4. Women whose follow up starts after W28 of pregnancy

1. Maintain ART but switch drugs that are potentially teratogenic  
2. Start ART at start of 2nd trimester is optimal  
3. Start ART at start of W28 of pregnancy (at the latest 12 weeks before delivery); start earlier if high plasma viral load or risk of prematurity  
4. Start ART immediately

**Antiretroviral regimen in pregnancy**

- Same as non pregnant,  
  - except avoid TDF, EFV  
  - ABC and NVP not to be initiated but continuation is possible if started before pregnancy  
  - Among PI/r, prefer LPV/r or SQV/r  
  - ZDV should be part of the regimen if possible

**Drugs contra-indicated during pregnancy**

- Efavirenz, ddI + d4T, TDF, Triple NRTI combinations

**IV zidovudine during labour**

- Benefit uncertain if Plasma HIV RNA < 50 c/ml

**Single dose nevirapine during labour**

- Not recommended

**Caesarean section**

- Indicated except if Plasma HIV RNA < 50 c/ml at W34-36
## Post-Exposure Prophylaxis

<table>
<thead>
<tr>
<th>Nature of exposure</th>
<th>Status of source patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous or intramuscular penetration with IV or IM needle, or intravascular device</td>
<td>HIV + Or serostatus unknown but presence of HIV risk factors</td>
</tr>
<tr>
<td>• Percutaneous injury with sharp instrument (lancet), IM or SC needle, suture needle</td>
<td>HIV +</td>
</tr>
<tr>
<td>• Contact &gt; 15 min of mucous membrane or non intact skin</td>
<td></td>
</tr>
<tr>
<td>Anal or vaginal sex</td>
<td>HIV + Or serostatus unknown but presence of HIV risk factors</td>
</tr>
<tr>
<td>Receptive oral sex with ejaculation</td>
<td>HIV +</td>
</tr>
<tr>
<td>Exchange of syringe, needle, preparation material or any other material</td>
<td>HIV +</td>
</tr>
</tbody>
</table>

- Rapid testing of the source patient for HCV and HIV (if HIV status unknown) recommended,
- If patient source HIV+ on ARV therapy, order genotyping testing if HIV-RNA > 1000 copies/μL
- PEP to be started ideally < 4 hours after the exposure, and no later than 48 hours
- Duration of PEP: 4 weeks
- PEP regimen: TDF/FTC (alternative: ZDV/3TC) + [LPV/r tablets 400/100 mg bid or SQV/r 1000/100 mg bid]

- Assess tolerability of ARV PEP regimen
- Transaminases, HCV-PCR and HCV serology at month 1 if source of exposure were HCV+ (observed or suspected)
- Repeat HIV serology after 2 and 4 months, syphilis serology after 1 month if sexual exposure

Within 48-72 hours
- Full sexual health screen in case of sexual exposure
- Follow-up:
  - HIV serology + HBV and HCV, pregnancy test (women) within 48 hours of exposure
  - Reevaluation of PEP indication by HIV expert
PANEL MEMBERS

Jens Lundgren (Chair),
Copenhagen, Denmark

Manuel Battegay,
Basel, Switzerland

Georg Behrens,
Hannover, Germany

Stephane De Wit,
Brussels, Belgium

Giovanni Guaraldi,
Modena, Italy

Christine Katlama,
Paris, France

Esteban Martinez,
Barcelona, Spain

Devi Nair,
London, UK

Bill Powderly,
Dublin, Ireland

Peter Reiss,
Amsterdam, The Netherlands

Jussi Sutinen,
Helsinki, Finland

Alessandra Vigano,
Milan, Italy

and the EACS executive committee

Acknowledgements: The guidelines panel have received helpful comments and suggestions from the following persons: Heiner Bucher, David Burger, Nina Friis-Møller, Jose Gatell, Markku Saraheimo, Signe Worm & Hannele Yki-Järvinen
Abbreviations used throughout this document

- ABC = abacavir
- ART = antiretroviral therapy
- ATV = atazanavir
- CVD = cardiovascular disease
- d4T = stavudine
- ddl = didanosine
- DRV = darunavir
- EFV = efavirenz
- HBV = hepatitis B virus
- HCV = hepatitis C virus
- HDL-c = HDL-cholesterol
- IHD = ischemic heart disease
- LDL-c = LDL-cholesterol
- IDV = indinavir
- LPV = lopinavir
- NFV = nelfinavir
- NNRTI = non-nucleoside reverse transcriptase inhibitors
- NRTI = nucleos(t)ide reverse transcriptase inhibitors
- NVP = nevirapine
- PI = protease inhibitors
- PI/r = protease inhibitors pharmacologically boosted with ritonavir
- RTV = ritonavir (if used as booster = /r)
- SQV = saquinavir
- TC = total cholesterol
- TG = triglycerides
- TDF = tenofovir
- TPV = tipranavir
- ZDV = zidovudine
HIV specific issues to be considered

In HIV infection, both uncontrolled replication of HIV, co-infections (e.g. HCV) and ART contribute to metabolic diseases. The prevention and management of metabolic diseases in HIV should take all these factors into consideration.

Health care professionals involved with the care of HIV-infected persons who are not familiar with the use of ART should consult HIV specialists before introducing or modifying any type of treatment that HIV patients receive.

Conversely, many HIV physicians are not specialists in metabolic diseases, and should seek proper consultation prior to engaging in the prevention and management of such conditions. Situations where consultation is generally recommended are indicated where appropriate in these guidelines.

Preventing or managing metabolic diseases in HIV often involves polypharmacy, which increases the risk of suboptimal adherence and hence may compromise the continued benefit of ART. Additionally, the possibility of drug-drug interactions with ART should be carefully considered prior to introducing any treatment. Several web-sites exist for this purpose: www.HIV-druginteractions.org, www.HIVpharmacology.com, www.AIDSinfo.nih.gov.

There is limited amount of evidence from randomised controlled trials on how to most effectively manage metabolic diseases in HIV. As a result management currently is mainly extrapolated from general medical guidelines. Based on future clinical research findings, these guidelines will be regularly updated, at www.eacs.eu. The guidelines posted on the web, as well as updated versions will contain much more detailed information and links to any other relevant websites.
in managing metabolic diseases

The current guidelines highlight metabolic diseases, which are seen frequently in the routine care of HIV-infected persons and those for which specific issues should be considered.

Other related conditions in the management of HIV disease that are not or not extensively discussed, but may be included in future versions are:

- **Renal impairment.** Both factors related to HIV and certain antiretroviral drugs may impair renal function. Various drugs used in HIV care may need dose adjustment in case of impaired renal function.

- **The contribution of HIV as well as ART to bone disease,** which may include loss of bone mineral content and aseptic necrosis of the femoral head, remains unclear. For the moment these pathologies should be managed as in the general population.

- **Sexual dysfunction** is frequently encountered and its management often requires a multidisciplinary approach that may include both expert psychological counselling and medical interventions.
### Screening for metabolic diseases in patients with HIV

<table>
<thead>
<tr>
<th><strong>Assessment</strong></th>
<th><strong>Which Patient?</strong></th>
<th><strong>Frequency of assessment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Family history for premature IHD, diabetes, hypertension</td>
<td>Every patient</td>
<td>At HIV-diagnosis</td>
</tr>
<tr>
<td>• Concomittant therapy against dyslipidaemia/hypertension/diabetes</td>
<td></td>
<td>At HIV-diagnosis, before start of ART, and annually thereafter unless specifically indicated</td>
</tr>
<tr>
<td>• Concomittant therapy with risk for diabetes/dyslipidaemia</td>
<td></td>
<td>At HIV-diagnosis, before start of ART, and annually thereafter unless specifically indicated</td>
</tr>
<tr>
<td>• Current lifestyle (alcohol use, smoking, aerobic exercise)</td>
<td></td>
<td>At HIV-diagnosis, before start of ART, and annually thereafter unless specifically indicated</td>
</tr>
<tr>
<td><strong>Lipids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Fasting TC</td>
<td>Every patient</td>
<td>At HIV-diagnosis, before start of ART, and annually thereafter unless specifically indicated</td>
</tr>
<tr>
<td>• Fasting TG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Fasting LDL-c+HDL-c</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glucose</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Fasting glucose</td>
<td>Every patient</td>
<td>At HIV-diagnosis, before start of ART, and annually thereafter unless specifically indicated</td>
</tr>
<tr>
<td><strong>Body composition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Body-mass index</td>
<td>Every patient</td>
<td>At HIV-diagnosis, before start of ART, annually thereafter</td>
</tr>
<tr>
<td>• Waist circumference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Waist-to-hip ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Clinical lipodystrophy assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Blood pressure</td>
<td>Every patient</td>
<td>HIV-diagnosis, before ART, annually thereafter unless specifically indicated</td>
</tr>
<tr>
<td><strong>Cardiovascular disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Risk assessment</td>
<td>Every patient</td>
<td>Before ART, and annually thereafter</td>
</tr>
<tr>
<td>• ECG</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Renal failure</strong></td>
<td>Patient receiving drugs cleared via the kidneys</td>
<td>Before initiation of drug in question, after 4 weeks, 6 months and if remaining normal then once annually</td>
</tr>
<tr>
<td>• Estimated glomerular filtration rate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

i Cardiovascular events in a first degree male relative < 55 years or in a first degree female relative < 65 years.

ii E.g. neuroleptic drugs including clozapin, olanzapin; pentamidine, glucocorticoids, IFN-a, thiazide diuretics, furosemide, phenytoin, diazoxide, and others.

iii Fasting defined as a time period without caloric intake of at least 8 hours.

iv Assessment and monitoring should increase in frequency in case of severe dyslipidaemia (see 26), elevated blood pressure (see 36) or elevated fasting blood glucose levels (see 32) and/or if medical interventions are instituted to correct these conditions.

v Oral glucose tolerance test may be considered if repeated fasting glucose levels are in the range of 6.1-6.9 mmol/L as it may reveal the presence of diabetes in such patients.

vi Use risk calculators for estimating 10-year risk of developing IHD events - [http://www.chip.dk/tools.aspx](http://www.chip.dk/tools.aspx). Of note, if individual patients receive medication to control dyslipidaemia and/or hypertension, interpretation of the estimation should be done with caution.

vii Use calculator to estimate glomerular filtration rate (eGFR) according to Cockcroft- Gault - [http://www.cphiv.dk/TOOLS.aspx](http://www.cphiv.dk/TOOLS.aspx)
Prevention of cardiovascular disease

Principles: The intensity of efforts to prevent cardiovascular disease depends on the absolute risk of IHD, using Framingham equation (see [http://www.cphiv.dk/tools.aspx](http://www.cphiv.dk/tools.aspx)). The preventive efforts are diverse in nature and require involvement of cardiologists, in particular if the risk of IHD is high.

### ESTIMATE RISK OF IHD IN NEXT 10 YEARS

<table>
<thead>
<tr>
<th>IHD risk &lt; 10%</th>
<th>IHD risk 10-20%</th>
<th>IHD &gt;20%, prior CVD, type II diabetes, type I diabetes with microalbuminuria</th>
</tr>
</thead>
</table>

Encourage life-style changes (diet, exercise, cessation of smoking), reduce visceral fat, reduce insulin resistance and treat hypertension.

<table>
<thead>
<tr>
<th>LDL-c cut off level: 5 mmol/L (≈190 mg/dL) (5-4 mmol/L (≈190 - 155 mg/dL))</th>
<th>LDL-c cut off level: 4 mmol/L (≈155 mg/dL) (4-3 mmol/L (≈155 - 115 mg/dL))</th>
<th>LDL-c cut off level: 3 mmol/L (≈115 mg/dL) (3-2 mmol/L (≈115 - 80 mg/dL))</th>
</tr>
</thead>
</table>

- **i** LDL-c cut off levels (unit: mmol/L (mg/dL)) are higher than in guidelines for the general population (more stringent levels where some experts would consider intervention also indicated in parenthesis below). In cases where LDL-c cannot be reliably calculated because of high triglyceride levels, the non-HDL-c target level should be used which is 0.8 mmol/L (30 mg/dl) higher than the corresponding LDL-c target.
- **ii** Options for ART modification include: (1) replacing PI/r) by NNRTI, by another PI/r) known to cause less metabolic disturbances (see 30) or by abacavir; should not be done if patient is known or suspected to harbour archived virus containing drug-related mutations against the new drug the patient is switched to (switch to abacavir should not be done in case (archived) thymidine analogue mutations are known or suspected to be present (e.g. due to prior use of suboptimal mono- or dual NRTI therapy)); (2) replacing d4T or ZDV by ABC or TDF. In patients with >20% 10 year risk or with prior CVD, the risk of CVD events and cardiac death will usually be higher than risk of progression to AIDS or death and in such patients a strategy to reduce risk of CVD by switching ART is hence most appropriate.

- **Blood-pressure**: ↑treat hypertension (see 36).
- **TG levels**: Uncertain if TG↑ contributes to CVD risk and whether it should be treated (see 28).
- **Low dose acetylsalicylic acid**: Only indicated in high-risk patients (right column above) as risk of intracerebral bleeding increased by 25% and extracerebral bleeding by 50%; harm likely exceeds benefit if risk of IHD is lower.
- **Combined benefit of interventions**: Per 10 mmHg reduction of systolic blood pressure, per 1 mmol/L reduction in TC and with use of low dose acetylsalicylic acid, each reduces risk of IHD by 20-25%; the effect is additive. Smoking cessation reduces risk of IHD the most - by 50% - and this is additive to other interventions.
### Life style interventions

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Principles</th>
</tr>
</thead>
</table>
| **Stop smoking counselling** | • Brief unambiguous statement about need to stop smoking  
  • If patient is not contemplating, try to motivate and emphasize positive short-term aspects (more money for better things, better taste for food, better skin, less dyspnoea), and long-term benefits (prevention of COPD, IHD, stroke, lung cancer)  
  • If patient is contemplating, try to fix stop date, establish reward system  
  • Use nicotine substitution (patch, chewing gum, spray), varenicline, or bupropion (note: bupropion may interact with PI and NNRTI) during weaning phase if necessary  
  • Consider referring patient to specialized stop smoking clinic  
  • Anticipate relapses, explain and consider them as part of the weaning process to final nicotine abstinence |
| **Diet counselling**   | • Limit intake of saturated fat and cholesterol  
  • Reduce total fat intake to < 30% and dietary cholesterol to <300mg/day  
  • Emphasize intake of vegetables, fruits, grain products with fibre  
  • Emphasize consumption of fish, poultry (without skin), lean meat and low fat dietary intake  
  • Keep caloric intake balanced with energy expenditure  
  • Consider referral to dietician, one week food and drink diary to discover 'hidden' calories  
  • Avoid binge eating ('yo-yo dieting')  
  • In patients with HIV-related wasting and dyslipidaemia address wasting first and consider referral to dietician  
  • Patients with BMI >30 kg/m² should be motivated to lose weight. Starvation diets are not recommended in an HIV-infected person (immune defence mechanisms potentially decreased). Malnutrition has to be addressed where observed. Normal BMI range: 18.5-24.9; Overweight: 25.0-29.9, Obesity: > 30.0 kg/m² |
| **Exercise**           | • Promote active lifestyle to prevent obesity, hypertension and diabetes  
  • Emphasize regular moderate-intensity exercise rather than vigorous exercise  
  • Encourage self-directed moderate level physical activity (take the stairs, bike or walk to work, cycling, swimming, hiking etc.)  
  • Achieve cardiovascular fitness (e.g. 30 minutes brisk walking 5/7 days a week)  
  • Maintain muscular strength and joint flexibility |

---

Management of dyslipidaemia

Conversely, the CVD risk implications from higher than normal levels of TG are less clear, as is the clinical benefit of treating moderate hypertriglyceridaemia. Diet, exercise and maintaining normal body weight tends to reduce dyslipidaemia; if not effective, consider change of ART and then consider lipid-lowering medication in high-risk patients (see 22).

### Drugs used to treat dyslipidaemia

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Drug</th>
<th>Dose</th>
<th>Benefit</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statin</td>
<td>Atorvastin</td>
<td>10-80 mg QD</td>
<td>LDL-c↓i</td>
<td>Gastrointestinal symptoms, headache, insomnia, rhabdomyolysis (rare) and toxic hepatitis</td>
</tr>
<tr>
<td></td>
<td>Fluvastin</td>
<td>20-80 mg QD</td>
<td>LDL-c↓i</td>
<td>Consider higher dose↓</td>
</tr>
<tr>
<td></td>
<td>Pravastin</td>
<td>20-80 mg QD</td>
<td>LDL-c↓i</td>
<td>Consider higher dose↓</td>
</tr>
<tr>
<td></td>
<td>Rosuvastin</td>
<td>5-40 mg QD</td>
<td>LDL-c↓ii</td>
<td>Consider higher dose↓</td>
</tr>
<tr>
<td></td>
<td>Simvastatin</td>
<td>10-80 mg QD</td>
<td>LDL-c↓</td>
<td>Consider higher dose↓</td>
</tr>
<tr>
<td>Cholesterol uptake↓</td>
<td>Ezetimibe</td>
<td>10 mg QD</td>
<td>LDL-c↓i</td>
<td>Gastrointestinal symptoms</td>
</tr>
<tr>
<td>Nicotinic acid derivative</td>
<td>Acipimox</td>
<td>1.0-1.5 g QD</td>
<td>TG↓</td>
<td>Flushing, rash, headache, gastrointestinal symptoms</td>
</tr>
<tr>
<td>Fibrate</td>
<td>Bezafibrate</td>
<td>400 mg QD</td>
<td>TG↓</td>
<td>Gastrointestinal symptoms, toxic hepatitis, myopathy and rhabdomyolysis</td>
</tr>
<tr>
<td></td>
<td>Fenofibrate</td>
<td>67-267 mg QD</td>
<td>TG↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ciprofibrate</td>
<td>100 mg QD</td>
<td>TG↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gemfibrozil</td>
<td>900 mg QD/600 bid</td>
<td>TG↓</td>
<td></td>
</tr>
<tr>
<td>Omega 3 acid ester</td>
<td>MaxEPA</td>
<td>5 g bid</td>
<td>TG↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Omacor</td>
<td>1-2 g bid</td>
<td>TG↓</td>
<td></td>
</tr>
</tbody>
</table>

i, ii, iii Expected range of reductions of LDL-c: i0.8-1.5 mmol/L (35-60 mg/dL), ii1.5-2.5 mmol/L (60-100 mmol/L), iii0.2-0.5 mmol/L (10-20 mg/dL)

iv, v The ART drug may induce (=less effect of statin, ↑dose gradually to achieve expected benefit↓) or inhibit (statin toxicity, ↓dose) the excretion of the statin.

vi Exception: If used with DRV/r, start with lower dose of pravastatin.
### Treatment recommendations

<table>
<thead>
<tr>
<th>Type of dyslipidaemia</th>
<th>First choice</th>
<th>Combination therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isolated hypercholesterolaemia</strong> (LDL-c &gt; cut-off (see 22))</td>
<td>Statin</td>
<td>+ Ezetimibe</td>
</tr>
<tr>
<td><strong>Combined hyperlipidaemia</strong> (LDL-c &gt; cut-off (see 22) and TG 5 - 10 mmol/L)</td>
<td>Statin</td>
<td>+ Fibrate (nicotinic acid derivative)</td>
</tr>
<tr>
<td><strong>Isolated hypertriglyceridaemia</strong> (TG 2.3-10 mmol/L)</td>
<td>Diet, alcohol abstinence</td>
<td>-</td>
</tr>
<tr>
<td><strong>Severe hypertriglyceridaemia</strong> (&gt; 10 mmol/L)</td>
<td>Fibrate</td>
<td>+ Omega 3 acid ester (nicotinic acid derivative)</td>
</tr>
<tr>
<td><strong>Isolated low HDL-c</strong> (&lt; 0.9 mmol/L)</td>
<td>Fibrate</td>
<td>+ Nicotinic acid derivative</td>
</tr>
</tbody>
</table>

---

i  Treatment goal is to reduce LDL-c < cut-off levels (see 22). Check lipids (fasting) prior to initiation of therapy, 4-12 weeks after initiation or modification of therapy, and annually once levels are below cut off levels. Consult with lipid expert if treatment goal cannot be reached.

ii  Check AST (< x 3 ULN) and CK (< x5 ULN) prior to initiation, 4-12 weeks after treatment initiation, and then annually if within normal range.

iii  It is not clear whether these levels of elevated TG carry an excess CVD risk; priority should be given to reducing LDL-c to below cut-off levels (see 22).

iv  Combination therapy of statin and gemfibrozil (and less so other fibrates) increases risk of rhabdomyolysis and should be avoided whenever possible.
Limited data from use of fusion inhibitors (enfuvirtide), integrase inhibitors (raltegravir), and CCR5 inhibitors (maraviroc) suggest these drugs to have little metabolic impact, but length of experience for some of these is limited.
## Prevention and Management of Lipodystrophy

### Lipoatrophy

**Prevention**
- Avoid d4T and ZDV or preemptively switch away from them

**Management**
- Modification of ART
  - Switch d4T or AZT to ABC or TDF:
    - Only ART modification proven to partially restore subcutaneous fat; increase in total limb fat ~400-500g/year
    - Risk of new toxicity (ABC hypersensitivity reaction?; TDF associated nephrotoxicity?)
  - Switch to regimen not including NRTIs
    - Increase in total limb fat ~400-500g/year
    - May increase risk of dyslipidaemia
    - Less data on virological safety

- Surgical intervention
  - Offered for cosmetic relief of facial lipoatrophy only; fillers may be absorbable (limited effect) or permanent (durability of desired cosmetic effect is unknown)
  - Limited randomized trials and no comparative studies of different approaches

### Lipohypertrophy

**Prevention**
- No proven strategy

**Management**
- Diet and exercise may reduce visceral adiposity:
  - Limited data, but possibly reduction of visceral adipose tissue and improvement in insulin sensitivity and blood lipids, especially in obesity associated with lipoatrophy
  - No prospective trials in HIV-infected patients to definitely indicate degree of diet and/or exercise needed to maintain reduction in visceral fat.
  - May worsen subcutaneous lipoatrophy

- Pharmacological interventions to treat lipohypertrophy have not been proven to provide long-term effects and may introduce new complications
  - Growth hormone
    - Decreases visceral adipose tissue
    - May worsen subcutaneous lipoatrophy, may worsen insulin resistance
  - Metformin
    - Decreases visceral adipose tissue in insulin resistant persons
    - May worsen subcutaneous lipoatrophy.
  - Surgical therapy can be considered for localised lipomas/buffalo humps
    - Duration of effect variable

---

\[i\] See [http://www.eacs.eu/guide/index.htm](http://www.eacs.eu/guide/index.htm) for list of arguments for and against the use of various types of fillers and some examples of specific types.
Treatment of type 2 diabetes

### Diagnostic criteria

<table>
<thead>
<tr>
<th></th>
<th>Fasting plasma glucose mmol/l (mg/dl)</th>
<th>Oral glucose tolerance test (OGTT) 2-h value mM (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>≥ 7.0 (126)</td>
<td>OR --- ≥ 11.1 (200)</td>
</tr>
<tr>
<td>Impaired glucose tolerance (IGT)</td>
<td>&lt; 7.0 (126)</td>
<td>AND --- 7.8 - 11.0 (140 - 199)</td>
</tr>
<tr>
<td>Impaired fasting glucose (IFG)</td>
<td>6.1 - 6.9 (110 - 125)</td>
<td>AND --- &lt; 7.8 (140)</td>
</tr>
</tbody>
</table>

i As defined by WHO and International Diabetes Federation (2005)

ii An abnormal finding should be repeated before confirming the diagnosis.

iii Is recommended in patients with fasting blood glucose 6.1 - 6.9 mmol/l (110 - 125 mg/dL) as it may diagnose patients with overt diabetes.

Both IGT and IFG increase CV morbidity and mortality, and increase the risk of developing diabetes by 4-6 fold. These patients should be targeted for lifestyle intervention, and their CV risk factors must be evaluated and treated.

### Interventions for treatment of diabetes (only interventions studied in persons receiving ART)

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Dose</th>
<th>Expected decrease in HbA1c (%)</th>
<th>Side-effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life-style intervention</td>
<td></td>
<td>1 - 2</td>
<td></td>
<td>Intra-abdominal and subcutaneous fat may ↓</td>
</tr>
<tr>
<td>Metformin</td>
<td>Start with 500-750mg qd/bid, increase to maximum tolerated dose of 2 (-3) g/d in 4-6 weeks</td>
<td>1.5</td>
<td>Gastrointestinal symptoms, lactic acidosis (rare). Contraindicated in renal insufficiency.</td>
<td>May worsen lipoatrophy</td>
</tr>
<tr>
<td>Thiazolidinediones:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>4-8mg/d, 15-45 mg/d</td>
<td>0.5 - 1.4</td>
<td>Fluid retention, cardiac failure, weight gain</td>
<td>See also 30</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>See below</td>
<td>No limit</td>
<td>Hypoglycemia, weight gain</td>
<td>Large doses may be required (1-2 IU/kg).</td>
</tr>
</tbody>
</table>

**Individualise treatment:** metformin for an overweight patient, pioglitazone (rosiglitazone) for a lipoatrophic patient. Metformin and glitazones can be combined. Diabetes is typically a progressive disease and medication must be modified accordingly. There are currently no data on the use of other antidiabetic drugs (sulfonylureas, glinides, exenatide, alpha-glucosidase inhibitors) in the treatment of HIV-infected patients taking ART. If treatment target cannot be reached with oral agents, insulin should be started. Start with 10 IU of long-acting insulin at bedtime. Teach the patient to self-monitor fasting glucose values and increase the dose by 2 units every 3 days until fasting plasma glucose < 6.1 mmol/l. Oral metformin should be continued with insulin therapy.

### Management of patients with diabetes

| Treatment goals: glucose control (HbA1c < 6.5-7.0% without hypoglycemias, fasting plasma glucose 4-6 mmol/l (73-110 mg/dL)); normal blood lipids and blood pressure (see 22 and 36). Acetylsalisylic acid (75-150mg/d) should be considered in all patients with diabetes. | Nephropathy and retinopathy screening should be performed as in diabetic patients without HIV. Consultation with a specialist in diabetology is recommended. Further reading: www.easd.org http://www.who.int/diabetes/publications |
# Prevention and management of hyperlactataemia

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Prevention / Diagnosis</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Use of d4T &gt; ZDV &gt; ddI</td>
<td>✓ Avoid d4T + ddI combination</td>
<td>✓ Hyperlactataemia: unexplained nausea, abdominal pain, hepatomegaly, weight loss</td>
</tr>
<tr>
<td>✓ HCV/HBV co-infection</td>
<td>✓ Routine monitoring of serum lactate levels not recommended - does not predict risk of lactic acidosis.</td>
<td>✓ Acidaemia: asthenia, dyspnoea, arrhythmias</td>
</tr>
<tr>
<td>✓ Use of ribavirin</td>
<td>✓ Measurement of serum lactate, bicarbonate &amp; arterial blood gases + pH indicated in case of symptoms suggestive of hyperlactataemia</td>
<td>✓ Guillain-Barré-like syndrome</td>
</tr>
<tr>
<td>✓ Liver disease</td>
<td>✓ Close monitoring if &gt; 1 risk factors</td>
<td></td>
</tr>
<tr>
<td>✓ Low CD4 cell count</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✓ Pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✓ Female sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✓ Obesity</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Management

<table>
<thead>
<tr>
<th>Serum Lactate (mmol/L)</th>
<th>Symptoms</th>
<th>Action</th>
</tr>
</thead>
</table>
| > 5 | Yes/No | ● Repeat test under standardized conditions to confirm & obtain arterial pH and bicarbonate\(^1\)  
   ● If confirmed, exclude other obvious causes  
   ✓ Arterial pH↓ and/or bicarbonate↓: Stop NRTIs  
   ✓ Arterial pH and/or bicarbonate normal: Consider switch from high to low risk NRTI & monitor carefully OR Stop NRTI's |
| 2-5 | Yes | ● Exclude other causes; if none found: watchfully follow up OR consider switch from high to low risk NRTI, OR Stop NRTI |
| 2-5 | No | ● Repeat test  
   ✓ if confirmed: watchfully follow up |
| <2 | None | |

\(^1\) Lactic acidosis is a rare but life-threatening situation usually associated with symptoms; high risk if serum lactate > 5 and especially > 10 mmol/L.

### Management of lactic acidosis (irrespective of serum-lactate level):
Admit patient. Stop NRTI's. Provide intravenous fluid support. Vitamin supplementation can be used (vitamin B complex forte 4 ml bid, riboflavin 20 mg bid, thiamine 100 mg bid; L-carnitine 1000 mg bid), although benefit not well documented.
### Management based on blood pressure

Recommendation for intervention from stratification based on blood pressure level and other risk factors

<table>
<thead>
<tr>
<th>Other risk factors and disease history</th>
<th>Blood pressure (mmHg) - levels</th>
<th>+ diagnosis &amp; grading of hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal: SBP 120-129 or DBP 80-84</td>
<td>Average risk</td>
<td>Low added risk</td>
</tr>
<tr>
<td>High normal: SBP 130-139 or DBP 85-89</td>
<td>Average risk</td>
<td>Moderate added risk</td>
</tr>
<tr>
<td>Grade 1: SBP 140-159 or DBP 90-99</td>
<td>Grade 2: SBP 160-179 or DBP 100-109</td>
<td>Grade 3: SBP &gt; 180 or DBP &gt; 110</td>
</tr>
<tr>
<td>No other risk factors</td>
<td>No BP intervention</td>
<td>Lifestyle changes for several months, then drug therapy</td>
</tr>
<tr>
<td>1-2 risk factors</td>
<td>Low added risk</td>
<td>Moderate added risk</td>
</tr>
<tr>
<td>Lifestyle changes</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes for several months, then drug therapy</td>
</tr>
<tr>
<td>3 or more risk factors or target organ disease or diabetes</td>
<td>Moderate added risk</td>
<td>High added risk</td>
</tr>
<tr>
<td>Lifestyle changes</td>
<td>Drug therapy and lifestyle changes</td>
<td>Drug therapy and lifestyle changes</td>
</tr>
<tr>
<td>Associated clinical conditions</td>
<td>High added risk</td>
<td>Very high added risk</td>
</tr>
<tr>
<td>Drug therapy and lifestyle changes</td>
<td>Immediate drug therapy and lifestyle changes</td>
<td>Immediate drug therapy and lifestyle changes</td>
</tr>
</tbody>
</table>
Management based on blood pressure measurement / diagnosis of hypertension -2/2-

i SBP = systolic blood pressure; DBP = diastolic blood pressure. Repeated blood pressure measurements should be used for stratification.

ii Recommended lifestyle interventions - see 24. Table adapted from J. Hypertension 2003; 21:1779-86.

iii Drug therapy can be initiated either with a low dose of a single agent or with a low dose combination of two agents. To reach target blood pressure, a proportion of patients will require combination therapy. For indications and contraindications for the major classes of antihypertensive drugs see (http://www.eacs.eu/guide/index.htm).

Medical treatment of uncomplicated hypertension: 1st choice: Thiazide or ACE-inhibitor, 2nd choice: Amlodipine (start with 5mg QD) or combination of two antihypertensives. Await (2-) 6 weeks of therapy to assess lowering of the blood-pressure. Grade 3 hypertension or lack of achievement of goal (see below) 2-6 weeks after commencing 2nd choice: consult hypertension expert.

Coadministration of PIs and calcium channel blockers (CCB) may result in significantly increased CCB-plasma concentrations resulting in increased risk of toxicity and prolonged effect; NNRTI's may decrease plasma concentrations of CCBs and reduce efficacy of CCB. Atenolol is the preferred beta-blocker when combined with ARVs; metoprolol plasma concentrations may be increased by boosted PIs. Consult a clinical pharmacologist or pharmacist when combining another antihypertensive agent with ARVs.

iv Risk factors include age (>45 years for men; > 55 years for women), smoking, family history of premature CVD.

v Target organ disease (left ventricular hypertrophy, ultrasound evidence of arterial wall thickening, microalbuminuria).

vi Associated clinical conditions (CVD, IHD, renal disease, peripheral vascular disease, advanced retinopathy).

Goals of treatment: Reduced SBP to <140/90 mmHg and to lower values if tolerated, with diabetes SBP<130/80 mmHg; SBP values <140 mmHg may be difficult to achieve in the elderly.

Warning: Caution regarding drug-drug interactions with antihypertensive drugs and ART.
European AIDS Clinical Society (EACS)

Guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults

**PANEL MEMBERS**

Jürgen Rockstroh (Chair),
Bonn, Germany

Sanjay Bhagani, London,
United Kingdom

Raffaele Bruno,
Pavia, Italy

Stefan Mauss,
Dusseldorf, Germany

Lars Peters,
Copenhagen, Denmark

Massimo Puoti,
Brescia, Italy

Vicente Soriano,
Madrid, Spain

Cristina Tural,
Barcelona, Spain

Yves Benhamou,
Paris, France
General recommendations for counseling in patients with HIV and hepatitis coinfection

SCREENING
1. All HIV-infected patients should be screened for hepatitis C at diagnosis and then on an annual basis. Screening for HCV in HIV-infected patients should be done using a third generation anti-HCV antibody test. A positive result should be followed by evaluation for the presence of HCV-RNA and the genotype should be determined. Patients with risk factors (ongoing IVDU, mucosal traumatic sex; consider recent outbreak of acute HCV in msm) with unexplained increase in hepatic transaminases and a negative HCV antibody test should be offered an HCV-RNA test for early detection of a recent infection.

2. HIV-infected patients should be screened for hepatitis A and B.

3. Hepatitis delta antibodies should be screened for in all HBsAg+ patients.

VACCINATION
4. Patients lacking anti-HAV IgG-antibodies and anti-HBV antibodies should be offered vaccination for the respective virus to prevent infection regardless of their CD4-count. The response to the vaccine is influenced by the CD4-count and level of HIV-RNA. In patients with low CD4-counts (<200/μl) and ongoing HIV replication, HAART should be initiated first prior to respective vaccination. In case of insufficient response (anti-HBs < 10 IU/l) re-vaccination should be considered. Double dose revaccination (40μg) at 3-4 vaccination time points (month 0, 1, 6 and 12) may help to improve response rates to vaccination. Patients who failed to seroconvert after hepatitis B vaccination and remain at risk for HBV-infection should be monitored annually for serological markers of HBV-infection.

PREVENTION/SUPPORT
5. Psychological, social and medical support should be made available to stop patients with a high alcohol intake from drinking or to strongly advise them to limit alcohol consumption.

6. Substitution therapy (opioid replacement therapy) in patients with active drug abuse as a step towards cessation of active drug use should be considered; help provided (e.g. through needle- and syringe-exchange programs) reduces the risk of reinfection including parenteral viral transmission (harm reduction strategy).

7. Since HBV and HIV and occasionally HCV are transmitted sexually, adequate counseling including the use of condoms is advisable. Mucosal traumatic sexual practices associated with a high risk of blood contact should be forbidden.
**Figure 1:**
Management and therapeutic options in compensated HBV/HIV co-infected patients with no immediate indication for anti-HIV therapy (CD4-count > 350/μl)

- **HBV DNA <2,000 IU/mL**
  - ✔ No treatment
  - ✔ Monitor every 6-12 months
  - ✔ Consider biopsy and treat if disease present**

- **HBV DNA ≥2,000 IU/mL**
  - ✔ PEG IFN**** (favorable response factors are: HBeAg + - HBV Genotype A - elevated ALT and low HBV-DNA)
  - ✔ Telbivudine (if HBV-DNA is still detectable at week 24 add adefovir to minimize resistance development risk)
  - ✔ Early HAART initiation including Tenofovir +3TC/FTC

- **ALT Normal**
  - ✔ Monitor ALT every 3-12 months
  - ✔ Consider biopsy and treat if disease present**

- **ALT Elevated**
  - ✔ PEG IFN**** (favorable response factors are: HBeAg + - HBV Genotype A - elevated ALT and low HBV-DNA)
  - ✔ Telbivudine (if HBV-DNA is still detectable at week 24 add adefovir to minimize resistance development risk)
  - ✔ Early HAART initiation including Tenofovir +3TC/FTC

---

* chronic HBV-infection defined as HBs-Ag+ > 6 months
** Serum HBV-DNA levels have been demonstrated to be associated with a linear increased risk for development of liver cirrhosis and HCC; please note that the calculation from copies to IU/ml varies depending on which respective test assay was used; in general 1 IU/ml equals around 5 copies or genome equivalents; one picogram HBV-DNA equals 2,8x10^10 genome/ml Metavir A2 and/or F2; Patients with replicating HBV and normal liver enzymes may have significant liver damage, therefore consider assessment of liver damage; this may be done using either liver biopsy or non-invasive tools, including serum fibrosis markers or fibroScan. While liver biopsy may provide additional information on inflammation and other lesions (e.g., steatosis), non-invasive markers can be used at more frequent intervals.
**** treatment length: 48 weeks for PEG INF; for the nucleoside analogues: HBsAg seroconversion + 6 mths. In those not requiring HAART and on treatment with telbivudine +/- adefovir, or those on HAART where nucleoside back-bone needs changing, anti-HBV therapy may be stopped cautiously in HBeAg+ patients who have achieved HBs- seroconversion or HBs- seroconversion for at least six months or, after HBs-seroconversion for at least six months in those who are HBeAg-.
Figure 2:
Management and therapeutic options in compensated or cirrhotic HBV/HIV co-infected patients with an indication for HIV treatment (CD4-count ≤ 350/μl or already on HAART)

Immediate indication for HIV treatment

- **HBV-DNA ≥ 2000 IU/ml**
  - Patients without HBV associated 3TC resistance
    - HAART including TDF + 3TC or FTC
  - Patients with HBV associated 3TC resistance
    - Substitute one NRTI by Tenofovir or add Tenofovir*

- **HBV-DNA < 2000 IU/ml**
  - HAART regimen of choice**

- **Patients with cirrhosis**
  - HAART including TDF + 3TC or FTC
  - Refer patient for liver transplantation evaluation if liver decompensation occurs

* if feasible and appropriate from the perspective of maintaining HIV suppression
In some cases of tenofovir intolerance (i.e. renal disease), entecavir 1 mg/day may be advisable.

** some experts strongly think that any HBV-infected patient requiring HAART should receive TDF +3TC or FTC unless history of TDF intolerance
1. HCV treatment offers the possibility of eradicating HCV within a defined treatment period. This is potentially advantageous for the subsequent management of the patient with HIV, and every patient should therefore be considered for treatment when the benefits of therapy outweigh the risks. This also needs to be seen in the context of faster liver fibrosis progression in HIV/HCV coinfection and with better HCV treatment outcome with improved management in these patients.

2. Information on liver fibrosis staging is important for making therapeutic decisions in coinfected patients. However, a liver biopsy is not mandatory for considering treatment of chronic HCV. Current therapy is particularly recommended in patients with a high likelihood of achieving sustained virological response (SVR): genotype 2 or 3 and patients infected with genotype 1 if the viral load is low (<400,000-500,000 IU/ml).

3. In case of the availability of a liver biopsy or Fibroscan demonstrating lower grades of liver fibrosis (F0-1), regardless of HCV genotype, treatment can be deferred. A liver disease stage assessment is especially important to perform in patients with a low chance of SVR.

4. The combination of Peg-IFN-alpha and ribavirin (RBV) is the treatment of choice for HCV infection. The standard dose for Peg-IFN 2a is 180μg once weekly, and for...
Peg-IFN 2b it is 1.5 μg/kg bodyweight once weekly. An initial weight adapted dose of RBV of 1000 (wt < 75kg) -1200 (wt > 75kg) mg once daily is recommended for all genotypes.

5. The primary aim of anti-HCV treatment is sustained virological response defined as undetectable serum HCV-RNA 24 weeks after the end of therapy, evaluated using sensitive molecular tests.

6. If chronic hepatitis C is detected early in the course of HIV infection (before the initiation of HAART is necessary), treatment for chronic HCV is advised. However, if a coinfected patient has severe immunodeficiency (CD4 count < 200 cells/μl), the CD4 count should be improved using HAART prior to commencing anti-HCV treatment. Patients with a CD4 relative percentage >25% are more likely to achieve SVR than lower CD4 percentage.

7. If an early virological response of at least 2 log10 reduction in HCV-RNA compared to baseline is not achieved at week 12, treatment should be stopped (figure 3).

8. During Peg-FN plus ribavirin therapy, ddi is contraindicated in patients with cirrhosis and should be avoided in patients with less severe liver disease. D4T and AZT also if possible should be avoided. The role of abacavir is uncertain at this point but cohort data at least suggests lower SVR results in patients receiving abacavir containing HAART.

9. In patients with acute HCV-infection HCV therapy is recommended if the HCV-RNA is confirmed positive (1 week apart) by week 12 post HCV transmission as SVR rates following treatment of acute HCV-infection are higher than for treatment of chronic HCV.
### Table 2:
Diagnostic procedures for hepatitis C in HIV-coinfection

<table>
<thead>
<tr>
<th>Diagnosis of hepatitis C</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV-Ab (positive 1-5 months after infection, may rarely be lost with immunosuppression)</td>
</tr>
<tr>
<td>HCV-RNA levels* (while not prognostic for progression, it is for response to treatment)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Status of liver damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grading of fibrosis (e.g. Fibroscan, liver biopsy, serum fibromarkers**)</td>
</tr>
<tr>
<td>Hepatic synthetic function (e.g. coagulation, protein, albumin, CHE)</td>
</tr>
<tr>
<td>Ultrasound and AFP every 6 months in cirrhotics (gastroscopy upon diagnosis of cirrhosis and every 1-2 years thereafter)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Before HCV treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV genotype and serum HCV-RNA</td>
</tr>
<tr>
<td>Autoantibodies (ANA, SMA, ANCA and LKM1)</td>
</tr>
<tr>
<td>TSH, thyroid autoantibodies if applicable;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monitoring of HCV treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Differential blood count and liver enzymes every 2-4 weeks</td>
</tr>
<tr>
<td>HCV-RNA at week 4 (to evaluate rapid virological response), week 12, 24, 48, (72 if applicable) and 24 weeks after stopping HCV therapy</td>
</tr>
<tr>
<td>CD4-count every 12 weeks</td>
</tr>
<tr>
<td>TSH every 12 weeks</td>
</tr>
</tbody>
</table>

* Low viral load defined as less than 400,000 IU/l when using pegIFN+RBV. There is no standard conversion formula for converting the amount of HCV-RNA reported in copies/ml to the amount reported in IU. The conversion factor ranges from about one to five HCV-RNA copies per IU.

**Serum fibromarkers include APRI, FIB-4, Hyaluronic acid, Fibrotest, Forns and other indexes
**Figure 3:**
Proposed optimal duration of HCV therapy in HCV/HIV-coinfected patients.

- **W4**
- **W12**
- **W24**
- **W48**
- **W72**

- **HCV-RNA neg**
  - **G2/3**
  - **24 weeks therapy * **
  - **HCV-RNA neg**
  - **G1/4**
  - **> 2 log drop in HCV-RNA**
  - **< 2 log drop in HCV-RNA**
  - **Stop**

- **HCV-RNA pos**
  - **G2/3**
  - **48 weeks therapy**
  - **G1/4**
  - **Stop**

* In patients with baseline low viral load (<400 000 IU/l) and minimal liver fibrosis.
**Table 2:**

Classification of and interventions for HCV/HIV-coinfected non-responders/relapsers to prior interferon-based therapies.

<table>
<thead>
<tr>
<th>Category</th>
<th>Recommended intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suboptimal prior treatment schedules:</td>
<td>Re-treatment using combination therapy with peginterferon plus weight-based ribavirin doses</td>
</tr>
<tr>
<td>✔ Interferon (monotherapy or with ribavirin)</td>
<td></td>
</tr>
<tr>
<td>✔ Low ribavirin doses</td>
<td></td>
</tr>
<tr>
<td>✔ Short length of therapy</td>
<td></td>
</tr>
<tr>
<td>Limiting toxicities &amp; poor adherence</td>
<td>Optimal support (SSRI, paracetamol/NSAID, pharmacists, use of hematopoietic growth factors)</td>
</tr>
<tr>
<td>Virological failure</td>
<td>✔ Maintenance therapy in patients with cirrhosis (Caveat: no data yet in coinfection, no indication in any country)</td>
</tr>
<tr>
<td></td>
<td>✔ Wait until new antivirals come to the market in the rest</td>
</tr>
</tbody>
</table>
The European AIDS Clinical Society (EACS) Guidelines are freely downloadable from www.eacs.eu. A declaration of potential conflict of interest of the panels members can be found at the same address.